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Background: Sublingual (s.l.) administration of soluble protein antigens, inactivated viruses, or virus-like particles
has been shown to induce broad immune responses in mucosal and extra-mucosal tissues. Recombinant
replication-defective adenovirus vectors (rADVs) infect mucosa surface and therefore can serve as a mucosal antigen
delivery vehicle. In this study we examined whether s.l. immunization with rADV encoding spike protein (S) (rADV-S)
of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) induces protective immunity against
SARS-CoV and could serve as a safe mucosal route for delivery of rADV.
Results: Here, we show that s.l. administration of rADV-S induced serum SARS-CoV neutralizing and airway IgA
antibodies in mice. These antibody responses are comparable to those induced by intranasal (i.n.) administration. In
addition, s.l. immunization induced antigen-specific CD8+ T cell responses in the lungs that are superior to those
induced by intramuscular immunization. Importantly, unlike i.n. administration, s.l. immunization with rADV did not
redirect the rADV vector to the olfactory bulb.
Conclusion: Our study indicates that s.l. immunization with rADV-S is safe and effective in induction of a broad
spectrum of immune responses and presumably protection against infection with SARS-CoV.
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The majority of microbial pathogens enter their hosts
through a mucosal site; hence, effective vaccines
should elicit immune responses at the site of infection
[1,2]. Ideally, vaccines against pathogens such as severe
acute respiratory syndrome-associated coronavirus
(SARS-CoV) which infects the airways should elicit
immune responses in the mucosa of the respiratory
tract [3]. Although mucosal application of vaccines is
attractive for many reasons, only few mucosal vaccines
[most of them are given by the oral route and only* Correspondence: mksong@ivi.int
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reproduction in any medium, provided the orone intranasal (i.n.) live-attenuated influenza vaccine]
have been approved for use in humans. Because oral
administration of vaccines has been proven difficult
for inducing immune responses in the respiratory tract
[2], i.n. delivery of vaccines has been selected as an at-
tractive alternative to injection. While i.n. vaccination
elicits strong local and systemic immune responses,
concerns about its safety have been raised following
reports of unacceptable neurological side-effects asso-
ciated with retrograde transport of antigens or adju-
vants through the olfactory epithelium [4-7].
Replication-defective adenovirus (rADV) vectors are
among the most attractive vectors for delivery of foreign
antigens [8-20]. ADVs infect their host through the airway
epithelium, and replicate in mucosal tissues of thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cosal vaccination with ADV has been shown to be effect-
ive at producing antibody (Ab) and T cell responses at the
site of immunization [20,22,23]. However, when applied
intranasally, ADV can enter the central nervous system
(CNS) through binding to olfactory neurons [7,24,25]. The
concerns call for alternative delivery routes.
The sublingual (s.l.) route has been extensively used
for administration of immunotherapeutic allergens as a
modality to induce suppression of type I allergic
responses [26-29]. We have shown that s.l. administra-
tion of a prototype soluble protein antigen with cholera
toxin (CT) adjuvant could induce Ab and cytotoxic T-
lymphocyte (CTL) responses comparable to those seen
after i.n. immunization [30]. In addition, s.l. administra-
tion of live influenza virus protected mice against influ-
enza virus challenge without redirecting the immunizing
virus to the CNS [31]. More recently, it has been shown
that s.l. administration of rAd5 vectors encoding HIV
proteins induced significant antigen-specific humoral
[32] and cellular immune responses [33], indicating that
s.l. route is suitable for rADV vaccines.
SARS-CoV is an enveloped virus containing a large
single-strand RNA genome with positive orientation.
The club-shaped peplomers radiating outwards from the
viral envelope are composed of oligomeric forms of the
~180 kDa viral spike (S) glycoprotein. The S protein not
only contains the receptor binding site and the putative
fusion peptide, but it is also a major antigenic determin-
ant of the virus and Abs targeting this protein neutralize
the virus in vitro and in vivo [34-36].
In this study, we explored the suitability of the s.l. route
for administering a replication-defective ADV encoding
truncated S protein (rADV-S) lacking cytoplasmatic and
transmembrane domains. The immune responses induced
upon s.l. immunization with rADV-S were compared to
those induced by i.n. and intramuscular (i.m.) routes. We
found that s.l. delivery of rADV-S induced systemic and
mucosal Abs, CD8+ T cell responses. Importantly, our
immunization strategy generated SARS-CoV neutralizing
antibodies (nAbs) at the titers that are presumably pro-
tective against the infection. In addition, we confirmed
that s.l., in contrast to i.n. administration, did not redirect
rADV to the olfactory bulb.
Results
Characterization of rADV expressing SARS-CoV S protein
To confirm the expression of S protein in vitro, 293 cells
were infected with rADV-S at 20 multiplicity of infection
(MOI) for 48 hrs. Cell lysates and culture supernatants
were collected and analyzed by Western blot. As shown
in Figure 1B, a specific ~ 120 kDa protein band corre-
sponding to the predicted size of the S protein, was
observed in rADV-S infected 293 cells but not in rADV-EGFP infected cells. The portion of the S1 domain
(S201-510) expressed in and purified from E. coli was
used as coating antigen in ELISA. The purified protein
was confirmed by Western blot using rabbit anti-SARS-
S1 Ab (Figure 1C).S.l. Administration of rADV induced mucosal Ab
responses
To compare the immune responses induced by different
delivery routes, we immunized s.l., i.n., or i.m. each
group of BALB/c mice three times 14 days apart with
either 2 × 107 or 1 × 108 plaque-forming unit (PFU) of
rADV-S. Sera from the animals were collected 2 weeks
after each immunization and tested for S protein-
specific IgG by ELISA. IgG titers were detected as soon
as 2 weeks after the first immunization regardless of de-
livery route. However, i.m. immunization induced the
highest S protein-specific IgG titers in the sera as com-
pared to i.n. and s.l. immunizations (Figure 2A). The
peak of IgG titers was reached in all groups upon second
immunization as third immunization did not signifi-
cantly increase the IgG titers.
Since SARS-CoV infects mucosa of the lungs, an ef-
fective vaccination strategy should induce specific im-
mune response in the lungs, the site of infection. I.n.
administration is well recognized for excellent induc-
tion of immune responses in mucosal compartments of
the respiratory tract [37,38]. We asked whether s.l.
immunization with rADV-S induces antigen-specific Ab
in the lungs. We examined the level of IgA specific for
SARS-S protein in Bronchoalveolar lavages (BAL) of
mice upon s.l. immunization. As shown in Figure 2B,
significant level of IgA specific for SARS-S protein was
observed in BAL of s.l. immunized mice 2 weeks after
the third immunization. The IgA level is comparable to
that seen in BAL of i.n. immunized mice.S.l. Administration of rADV induced SARS-CoV nAb
nAbs against the S protein are considered a surrogate of
protection against infection with the SARS-CoV [39,40].
We examined whether s.l. immunization with rADV-S
induces nAbs. Groups of 6 mice each were immunized
three times 2 weeks apart with rADV-S via either s.l., i.n.,
or i.m. route. Two weeks after the third immunization sera
were collected and analyzed for SARS-CoV neutralization
using microneutralization assay. As shown in Figure 3, all
immunization routes induced significant levels of nAbs.
The endpoint titers of nAbs are far above the titer of 1/35
that is considered to be protective in mice [36]. Thus, the
results demonstrate that s.l. immunization with rADV-S
induced high titer of nAbs against SARS-CoV infection,
presumably protection against infection with SARS.
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Figure 1 Construction of rADV vector expressing SARS-CoV S glycoprotein and expression of S proteins in 293 T cells and bacteria. (A)
The gene encoding codon-optimized SARS-S protein without helical regions, transmembrane domain and cytoplasmic domain was inserted into
pShuttle vector to construct the rADV expressing the SARS-S protein. (B) 293 T cells were infected with rADV-S or rADV-EGFP and the S protein in
the cell lysate was detected by Western blot. (C) DNA for SARS-S protein (amino acids 201–510) was inserted into pET15b vector to express
recombinant S protein from E. coli. The protein was purified by His-tag affinity chromatography and detected by Western blot.
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induced virus-specific CD8+ T cell responses in the
respiratory tract
It has been suggested that CD8+ T cell responses are im-
portant for clearance of other coronaviruses such as
mouse hepatitis virus [41,42]. Therefore, we examined
whether the administration of rADV-S via s.l., i.n., or i.m.
route induces CD8+ T cell responses in the lungs and
spleens. Ten days after the third vaccination, antigen-
specific CD8+ T cells binding to MHC I tetramers contai-
ning the H-2Kd-restricted SARS-CoV S epitope366-374
(CYGVSATKL) [43] and producing intracellular IFN-γ
after in vitro re-stimulation with CYGVSATKL peptide
were determined. As shown in Figure 4A, i.n. and s.l.
immunization routes induced significantly higher percen-





















































































Figure 2 SARS-CoV S-specific humoral immune responses in the imm
route. Sera were collected two weeks after each vaccination and BAL was c
sera (A) and S-specific IgA titers in BAL (B) were determined by ELISA. The
three separate experiments.and 6.4%, respectively) as compared to i.m route (3.2%).
Similarly, i.n. and s.l. immunization routes induced signifi-
cantly higher percentages of IFN-γ-producing CD8+ T
cells in the lung (10.5 and 8.5%, respectively) in response
to SARS S protein. As expected, i.n. and s.l. immunization
routes induced lower percentages of SARS S-specific
CD8+ T cell and IFN-γ-producing CD8+ T cell in the
spleens (Figure 4B) as compared to that induced by i.m.
immunization. The results clearly demonstrate that s.l.
and i.n. administrations of rADV-S are equally efficient in
induction of CD8+ T cell responses in the lungs.
S.l. Administration of rADV did not redirect virus to
olfactory bulb
It has been reported that the i.n. administration of rADV




















































unized mice. Mice were immunized with rADV-S by s.l., i.n., or i.m.
ollected two weeks after the last immunization. S-specific IgG titers in
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Figure 3 SARS-CoV neutralizing activity of Sera. Mice were
immunized three times with rADV-S 2 × 107 PFU by s.l., i.n., or i.m.
route. Sera were tested to measure the Abs that would neutralize
the infectivity of 100 TCID50 of SARS-CoV in Vero cell monolayers.
Neutralization titers were determined by the CPE of SARS-CoV on
Vero cell. The dotted line indicates the limitation of detection. The
results are expressed as the means + SD.
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redirects the virus vector to the olfactory bulb, 1 × 108
PFU of rADV were administered either intranasally or
sublingually. Twenty-four hours later, the olfactory bulbs
were collected and the presence of adenoviral DNA was
determined by PCR. As shown in Table 1, no adenoviral
DNA was detected in olfactory bulbs of s.l. immunized
mice. In contrast, adenoviral DNA was detected in olfac-
tory bulbs of all 8 i.n. immunized mice. Viral DNA was
detected in the lungs of all s.l. immunized mice, as was
the case for mice immunized intranasally.
Discussion
In this study, we demonstrate that s.l. administration of
the rADV-S induced SARS-CoV S-specific immune
responses in mucosal and systemic compartments. The
results are in the line of our previous studies and those
of others indicating that s.l. immunization induced
broad spectrum of specific immune responses [30,31].
Indeed, s.l. immunization induced immune responses in
respiratory [30] and vaginal tracts [44-46]. The former
is not exceptional for our ADV encoding SARS-CoV
since the rADV-S induced significant immune responses
in respiratory tracts and systemic compartments. It is
noteworthy that protein S specific IgA Ab response in
BAL could be only induced when the animals were
immunized either intranasally or sublingually. This
characteristic of rADV is particularly important for the
development of mucosal vaccines against respiratory
pathogens. The levels of IgG and IgA induced in the
blood upon s.l. immunization are comparable to those
elicited by i.n. immunization which has been consideredto be the best immunization route for induction of
broad mucosal and systemic immune responses [30], in-
dicating that s.l. immunization with rADV-S is an op-
tion for effective induction of systemic immunity.
Importantly, s.l. immunization with rADV-S induced
nAb at the level that is presumably protective against
the challenge with live virus. It has been reported that
nAbs targeting S protein play an important role in
protection against SARS-CoV infection [47]. We found
all immunization routes including s.l. immunization
induced nAb titers above 1/35 that is considered to be
protective in mice [36], indicating that our designed
rADV-S is suitable for induction of protective immunity
to wild type SARS-CoV.
In consideration of the emergence of nAb escape mu-
tant and clinical observations in SARS patients who
showed a decrease of CD8+ memory T cells [48], it is
desirable to develop a SARS vaccine which can induce
both humoral and cellular immune responses. Here, we
showed that s.l. and i.n. immunizations of rADV-S
induced higher levels of SARS-CoV S-specific CD8 T
cell responses in the lung than that of i.m.
immunization. The findings are in consistence with
other studies showing that rADV expressing S protein
could induce cellular immune responses [49,50]. Thus
our immunization strategy involving rADV-S delivery
through s.l. mucosa offers readily a tool to combat po-
tential newly emerging SARS mutant.
There is a concern about pre-existing Abs against
adenovirus in the human population that may prevent
the immunization with rADV vector [51]. We showed
that S-specific IgG Ab responses induced after the first
immunization could be further boosted by a second ad-
ministration of the rADV vector vaccine, but the third
round of vaccination failed to induce an increase in the
serum Ab levels. It is likely that the IgG titers induced
after the second immunization already reached their
maximum and could not be further boosted. Similarly,
higher levels of serum specific IgG induced upon first
i.m. immunization as compared to that induced by i.n.
or s.l. immunization could not be further boosted.
It has been shown that i.n. but not i.m. immunization
with rADV encoding SARS S and nucleocapsid (N) pro-
teins significantly reduced SARS-CoV titer in the lungs
after challenge, suggesting that i.n. immunization
induced protective immune responses in the lungs, the
site of infection [3]. Although i.n. delivery of vaccines
induces effectively protective immunity, several observa-
tions raised safety concerns for its use in humans [7,25].
I.n. delivery of protein antigen together with CT as an
adjuvant redirects antigen to CNS [31] and i.n. delivery
of inactivated influenza vaccine caused Bell’s palsy in
some human recipients [52]. In addition, i.n. delivery of















































Figure 4 Detection of S366-374 epitope-specific and IFN-γ secreting CD8
+ T lymphocytes in the mice vaccinated with rADV-S. Mice were
immunized three times with rADV-S 1 × 108 PFU by s.l., i.n., or i.m. route. Lung (A) and spleen (B) lymphocytes were harvested 10 days after the
final immunization and were tested by flow cytometric analysis after staining with S366-374 tetramer, IFN-γ, CD8 and CD44.
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Table 1 The distribution of rADV-EGFP in the lung and
olfactory bulb of mice after i.n. or s.l. administration
Route PCR positive in lung a PCR positive in olfactory bulb
i.n. 8/8 8/8
s.l. 8/8 0/8
a BALB/c mice were immunized with rADV-EGFP by i.n. or s.l. injection and
next day, the lung and olfactory bulb were removed from the immunized
mice. DNA was purified from the lungs and olfactory bulbs by using DNeasy
tissue kit. The results were determined by PCR as described in Materials and
Methods.
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tive immunization route for safe and effective induction
of mucosal immune responses. Oral vaccination has
been known to induce mucosal immunity and is safer
than i.n. immunization, however degradation of the vac-
cine by the acidic pH and proteolytic enzymes in the
gastrointestinal tract complicate the oral vaccination [2].
We chosen s.l. route as it was used for allergen immuno-
therapy [26] and was shown to be safe.
The s.l. delivery of rAd vectors expressing HIV-Gag
was shown to induce Ag-specific CTL responses in mice
even with preexisting immunity to Ad5 [33]. In addition,
a recent study demonstrated that s.l. administration of
rAd5 vector expressing HIV-Env was effective in pene-
trating the sublingual epithelium and induced Ag-
specific mucosal Ab responses without adjuvant [32].
The present study describes a finding that s.l. delivery
of rADV-S could induce systemic IgG and airway IgA
SARS-CoV nAb as well as CD8+ T cell responses in
mice. In contrary to i.n. administration, s.l. delivery of
rADV does not redirect the rADV to the CNS. Our data
indicated that s.l. administration could be an alternative
mucosal route for safe and effective vaccination with
rADV.
Conclusions
The s.l. delivery of rADV-S induced humoral and cellular
immune responses without accumulation of rADV in ol-
factory bulb. Importantly, these immune responses are
comparable with those induced by i.n. administration.
Thus, our study suggests that s.l. immunization with
rADV-S offers a novel safe and effective vaccination
strategy to combat SARS-CoV.
Materials and methods
Construction of rADV expressing SARS-CoV S protein
The ectodomain (amino acids 14–891) of the SARS-
CoV S protein lacking the transmembrane domain and
the cytoplasmatic tail was codon-optimized for high-
level expression in mammalian cells and synthesized by
GenScript Co. (Piscataway, NJ). The natural signal se-
quence was replaced by that of tissue plasminogen
activator. Helical regions together with transmembrane
domain and cytoplasmic domain were deleted aspreviously reported [39]. Briefly, rADV expressing SARS-
CoV S gene was generated using the AdEasy™ Vector
System according to the manufacturer’s instructions (Stra-
tagene, La Jolla, CA). To inhibit the expression of SARS-
CoV S gene during the course of ADV production, a
tetracycline-regulated expression system was adopted. Two
tetracycline operator sequences derived from pcDNA4/TO
(Invitrogen, Carlsbad, CA) have been inserted between the
TATA box of the CMV promoter of pShuttle-CMV (Stra-
tagene), resulting in pShuttle-TetO2. After subcloning of
SARS-CoV S gene into pShuttle-TetO2 (Figure 1A), this
was co-transformed with adenoviral backbone vector,
pAdEasy, into Escherichia coli (E. coli) BJ5183 by electro-
poration to achieve homologous recombination. The
resulting construct was transfected into T-Rex-293 cells
(Invitrogen) by the calcium phosphate co-precipitation
method. T-Rex-293 cells were maintained according to the
manual. Recombinant ADV was isolated from a single
plaque, expanded in T-Rex-293 cells, and purified by
double cesium chloride ultracentrifugation. The purified
viruses were extensively dialyzed against 10 mM Tris, 5%
sucrose, 2 mM MgCl2 and stored in aliquots at −80°C
until use. Titers of ADV were determined by Tissue
culture infectious dose 50 (TCID50) and by plaque assays
in T-Rex-293 cells.
Western blot analysis
The rADV-S infected 293 T cell lysate was separated by
10% SDS-PAGE. After electrophoretic transfer to nitro-
cellulose membrane (Schleicher & Schuell, Germany),
the membrane was blocked with Tris-buffered saline
(TBS) containing 5% skim milk and incubated with
rabbit anti-SARS-S1 Ab (kindly provided by Chiron/
Novartis, Italy) at a 1:3,000 dilution in TBST (TBS and
0.05% Tween 20) containing 5% skim milk for 1 hr
at room temperature. After washing with TBST, the
membranes were probed with incubation with goat-anti-
rabbit Immunoglobulin G (IgG) conjugated to horserad-
ish peroxidase (Santa Cruz Biotechnology, Santa Cruz,
CA) at a 1:3,000 dilution in TBST containing 5% skim
milk and detected by chromogenic substrate (ECL kit;
Amersham Pharmacia Biotech Inc., Piscataway, NJ).
Immunizations
The immunization schedule is summarized in Table 2.
Six-week-old female BALB/c mice (Orient, Korea) were
maintained under specific pathogen-free conditions and
all studies were approved by Institutional Animal Care
and Use Committee (IACUC) at the International Vac-
cine Institute (2010–015). Mice were immunized i.m.
with rADV-S 2 × 107 PFU in 100 μl phosphate-buffered
saline (PBS), i.n. or s.l. with rADV-S 2 × 107 or 1 × 108
PFU in 20 μl of PBS [30]. In each experiment, mice
(n = 6) were immunized three times at 2-week intervals.
Table 2 Immunization schedule
Group 1st (day 0) 2nd (day 14) 3rd (day 28) Routes a
1 rADV-Mock rADV-Mock rADV-Mock i.m.
2 rADV-S 2 × 107 rADV-S 2 × 107 rADV-S 2 × 107 i.m.
3 rADV-S 2 × 107 rADV-S 2 × 107 rADV-S 2 × 107 i.n.
4 rADV-S 1 × 108 rADV-S 1 × 108 rADV-S 1 × 108 i.n.
5 rADV-S 2 × 107 rADV-S 2 × 107 rADV-S 2 × 107 s.l.
6 rADV-S 1 × 108 rADV-S 1 × 108 rADV-S 1 × 108 s.l.
a Groups of six BALB/c mice were immunized s.l., i.n., or i.m. with rADV-S three
times at 2-week intervals.
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rADV-Mock (2 × 107 PFU/mouse).Sample collection
Blood was collected from the retro-orbital plexus 2 weeks
after each immunization, followed by incubation at room
temperature for 30 min. Sera were obtained from the
blood by centrifugation for 10 min at 13,000 rpm.
Bronchoalveolar lavages (BAL) were collected on day 43
under anesthesia by repeated intra-tracheal flushing and
aspiration of 500 μl of PBS per lung of mouse.ELISA
SARS-CoV S-specific Ab titers were determined by
enzyme-linked immunosorbent assay (ELISA). Truncated
SARS-CoV S protein (amino acids 201–510) was used as
antigen. The gene encoding truncated S (residues 201–
510) was inserted into pET15b vector (Novagen, Madison,
WI). The protein was expressed in E. coli BL21 (DE3)
(Novagen) and purified by Talon metal affinity column
(Clontech, Palo Alto, CA). To measure the Ab responses,
either the purified SARS-CoV S1 protein (amino acids
201–510) or a truncated S protein with a transmembrane
deletion (Protein sciences corporation, Meriden, CT) was
diluted to 2 μg/ml with 50 mM Sodiumbicarbonate buffer
(pH 9.6). Microtiter plates (Nunc, Denmark) were pre-
coated with 100 μl of the diluted protein per well and
incubated overnight at 4°C. The plates were washed with
PBS and blocked with 5% skim milk in PBS for 1 hr at
room temperature. 100 μl of 2-fold serial dilution of sam-
ples in blocking buffer were added to each well and incu-
bated for 1 hr at 37°C, followed by the addition of 1:3,000
diluted horseradish peroxidase-conjugated goat anti-
mouse IgG or IgA (Santa Cruz biotechnology). After incu-
bation for 1 hr at room temperature, 100 μl of peroxidase
substrate tetramethylbenzidine (TMB) (Millipore, Bedford,
MA) was added to each well. The reaction was stopped by
adding 0.5 N HCl. The absorbance at wavelength 450 nm
was recorded by a microplate reader (Molecular Devices,
Sunnyvale, CA). The endpoint titer was determined by O.
D. cut-off values of 0.2.Virus neutralization assay
The neutralization assay using active SARS-CoV was car-
ried out in a biosafety level 3 laboratory. Virus microneu-
tralization assay was performed as described previously
[35]. Briefly, two-fold serial dilutions of heat-inactivated
(30 min., 56°C) sera were tested against 100 TCID50 of
SARS-CoV in Vero cell monolayers. The cytopathic effect
(CPE) of SARS-CoV on Vero cell monolayers was read on
day 4 and the neutralization titer was calculated by the
Spearman/Karber formula [53].
Flow cytometry analyses
For MHC class I tetramer staining, recombinant MHC
class I Kd/SARS-CoV complexes were generated using
the procedure described by D. Busch and E. Pamer
(Yale University, New Haven, CT) [54]. Briefly, H-2Kd
heavy chain-biotinylation site fusion and human β2-
microglobulin were expressed in E. coli, purified from
inclusion bodies, solubilized, and refolded in the
presence of corresponding CYGVSATKL (S366-374)
SARS-CoV peptide, a major CD8+ T cell epitope [43].
Complexes were then enzymatically biotinylated by
BirA ligase (Avidity, Denver, CO) and were purified by
Superdex-75 gel filtration and Mono-Q anion exchange
chromatography (Amersham Pharmacia Biotech Inc.).
The biotinylated monomer complexes were tetramer-
ized with PE-labeled streptavidin (Molecular Probes,
Eugene, OR). Tetramers were stored at 5 mg/ml in PBS
(pH 8.0) containing 0.02% sodium azide, 1 μg/ml pep-
statin, 1 μg/ml leupeptin, and 0.5 mM EDTA at 4°C.
The lungs were perfused with 5 ml of PBS containing 10
U/ml heparin (Sigma-Aldrich) through the right ven-
tricle using a syringe fitted with 25-gauge needle. The
lungs were then removed and placed into RPMI
medium supplemented with glutamine, gentamicin,
penicillin G, and 10% fetal bovine serum (FBS)
(HyClone, Logan, UT). The tissues were then processed
through a steel screen to obtain single cell suspension,
and particulate matter was removed by passing through
70 μm Falcon cell strainer (BD Labware). Freshly
explanted lung cells were then purified by Percoll dens-
ity gradient centrifugation. Spleen cells from immunized
mice were resuspended in complete IMDM at a concen-
tration of 1 × 107 cells/ml. A total of 100 μl of these cells
(1 × 106 cells) were stained for CD8 (clone 53–6.7),
CD44 (clone IM7), and Kd/SARS-CoV tetramer and
samples were acquired on FACSCalibur™ (BD Bios-
ciences, San Jose, CA). For intracellular staining, the
cells were first stained for CD8 and CD44, washed, fixed
and permeabilized with FACS buffer containing 0.5%
saponin (Sigma-Aldrich). Then, the cells were stained
with PE-conjugated anti-IFN-γ (XMG1.2) (eBioscience,
Inc., San Diego, CA) or its control isotype Ab (rat IgG1)
(eBioscience). Gates were set on lymphocytes by
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lyzed using WinMDI version 2.9 software (The Scripps
Research Institute, La Jolla, CA).
Detection of DNA in tissues
Mice were administered either i.n. or s.l. with 1 × 108
PFU of rADV-EGFP in 20 μl PBS. The olfactory bulbs
and lungs were removed from the mice 24 hrs after the
administration of rADV-EGFP. DNA was isolated using
the DNeasy Tissue Kit (Qiagen, Valencia, CA) according
to the manufacturer’s protocol.
The EGFP gene was amplified by polymerase chain reac-
tion (PCR) using a forward primer (5’-CCGGGGATCCG
GTGAGCAAGGGCGAGGAG-3’) and a reverse primer
(5’-CCGGAAGCTTTCTTGTACAGCTCGTCCAT-3’). PCR
was performed under the following conditions: 5 min at
95°C denaturation, 30 cycles: 30s at 95°C, 30s at 55°C,
1 min at 72°C; 10 min at 72°C additional extension. The
PCR products were loaded on 1% agarose gel.
Statistical analysis
Statistical differences between experimental and control
groups were determined by unpaired Student’s t test. A
P value of less than 0.05 was considered significant.
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